Abstract 161: Stem Cell Transplantation Reverses Ischemic Mitral Regurgitation
Background: Ischemic Mitral Regurgitation (IMR) worsens prognosis in ischemic heart failure. As treatment options are limited, we tested the hypothesis that transcatheter intramyocardial injections of autologous bone marrow (BM) progenitor cells will prevent the natural history of deterioration and will improve IMR.
Methods: Eight ischemic cardiomyopathy patients (all males, 56.5±13 years old) underwent bone marrow aspiration followed by transcatheter injection of autologous bone marrow progenitor cells (4 patients got mononuclear cells, 4 patients got mesenchymal stem cells). Cardiac MRI and echocardiogram were conducted at baseline, 3, 6, and 12 months after cell transplantation.
Results: Five patients (57.8±15.8 years old) improved Ischemic MR and improved their left ventricular ejection fraction (LVEF) from 39±9% to 48±7.5% (p=0.02), left ventricular end systolic diameter (LVESD) from 4.7±0.7 cm to 3.7±0.6 cm (p=0.02), and left atrial (LA) diameter from 4.1±1.1 cm to 3.1±0.5 cm (p=0.05). A significant difference was observed in ΔLVESD% (p=0.03). No cell type preference was documented.
Conclusion: 1 year follow up post transcatheter intramyocardial injections of autologous BM cells in chronic ischemic cardiomyopathy patients demonstrated a significant improvement in Ischemic MR in 5 patients without worsening of MR in the other 3. These findings suggest that stem cell transplantation could have a major impact on ischemic MR and reverse ischemic MR.
Moderate IMR No IMR
- © 2012 by American Heart Association, Inc.